Ehave CEO Benjamin Kaplan to be Featured on Psychedelic Spotlight Segment of New to the Street Airing on NewsMax on Sunday March 14th at 10:00 AM EST and Fox Business March 15th at 7:30 PM EST
Ehave, Inc. (EHVVF), a provider of digital therapeutics in the psychedelic and mental health sectors, announced that its CEO, Benjamin Kaplan, will appear on the Psychedelic Spotlight segment of New to the Street. The segment will air on NewsMax on March 14th at 10:00 AM EST and on Fox Business on March 15th at 7:30 PM EST. This appearance is an opportunity for shareholders to gain insight into Ehave and the psychedelic sector. Ehave focuses on improving care for brain disorders through innovations like the Ehave Telemetry Portal.
- CEO Benjamin Kaplan will be featured on New to the Street, potentially increasing visibility for Ehave.
- Engagement with shareholders through media appearances may boost investor confidence.
- None.
MIAMI, March 12, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today CEO and psychedelic thought leader, Benjamin Kaplan, will be featured on the Psychedelic Spotlight segment of New to the Street. The program will air on NewsMax on Sunday March 14th at 10:00 AM EST and Fox Business March 15th at 7:30 PM EST.
Shareholders and interested parties are invited to watch or record Mr. Kaplan for a first hand overview of both Ehave and the psychedelic sector.
Additional Ehave Inc. Information
We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.
The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.
Please follow Ehave on Twitter @Ehaveinc1
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.
Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
Contact: Ehave Inc
Media Inquiries: Gabe Rodriguez
Gabe@Ehave.com
Investor Relations:
Email: Ir@Ehave.com
Phone: (623) 261-9046
FAQ
What is Ehave, Inc.'s stock symbol?
When will Benjamin Kaplan appear on New to the Street?
What is the focus of Ehave, Inc.?
How can shareholders engage with Ehave, Inc.?
